7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors

A method of treating a cancer expressing mutant IDH1 or mutant IDH2 in a patient, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the Formula:

• wherein:
• R1 is —CH2CH(CH3)2, —CH2CH3, —CH2CH2OCH3, or —CH2-cyclopropyl;
• R2 is —CH3 or —CH2CH3;
• or
• a pharmaceutically acceptable salt thereof,
• wherein the cancer is glioma, glioblastoma, glioblastoma multiforme, astrocytomas, oligodendrogliomas, paraganglioma, fibrosarcoma, angioimmunoblastic T-cell lymphoma (AITL), myelodysplastic syndrome (MDS), B cell acute lymphoblastic leukemia (B-ALL), thyroid cancer, colorectal cancer, acute myeloid leukemia (AML), melanoma, prostate cancer, chondrosarcoma or cholangiocarcinoma.